Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2011

Filing Date
Filed February 24, 2012
Period End
December 31, 2011
Security
IEX
One revenue dollarkept$0.11
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Material agreement8-K · Jun ’19Jun ’19
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed February 24, 2012. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation's 2011 Form 10-K reports net sales of $1,838.5 milliona, up 22% from $1,513.1 million in 2010, with organic sales up 9%, 11% from seven acquisitions, and 2% favorable currency translation.

Operating income rose to $304.7 millionb (16.6% of sales) and net income increased 23% to $193.9 million, with diluted EPS of $2.32 versus $1.90. Growth was driven largely by the CVI Melles Griot acquisition in June 2011 for $393.3 million in cash, funded mainly by revolver borrowings and the December 2011 issuance of $350.0 million 4.2% senior notes. Total borrowings rose to $808.8 million from $527.9 million, while the interest coverage ratio was 12.4 to 1 and the leverage ratio 2.2 to 1 against covenant limits of 3.0 and 3.25.

The company's four segments were Fluid & Metering Technologies (44% of sales, 45% of operating income), Health & Science Technologies (34% of sales, 31% of operating income), Dispensing Equipment (6% of sales, 4% of operating income), and Fire & Safety/Diversified Products (16% of sales, 20% of operating income). Roughly 53% of 2011 sales were to customers outside the U.S. For 2012, management expects mid-single digit organic growth and fully diluted EPS of $2.74 to $2.82c. Operating cash flow was $217.2 million, and capital expenditures were $34.5 million.

Goodwill of $1,431.4 milliond and intangible assets of $382.2 million together represent a substantial share of total assets of $2,836.1 million, a risk the filing highlights. The company also disclosed a $125.0 million share repurchase authorization, with no shares repurchased in 2011 or 2010, and an asbestos-related lawsuit exposure that management does not currently believe will have a material adverse effect.

Key Highlights

  1. Net sales rose 22% to $1,838.5 million in 2011, with organic growth of 9%.
  2. Operating income increased to $304.7 million, a 22% gain, with operating margin of 16.6% of sales.
  3. Net income grew 23% to $193.9 million, and diluted EPS reached $2.32 versus $1.90 in 2010.
  4. The CVI Melles Griot acquisition for $393.3 million in cash, closed June 10, 2011, was a major driver of growth and was largely funded by revolver borrowings.
  5. Total borrowings increased to $808.8 million, and the company issued $350.0 million of 4.2% senior notes due 2021 in December 2011.
  6. Management expects mid-single digit organic growth in 2012 and fully diluted EPS of $2.74 to $2.82.
  7. Goodwill and intangible assets totaled $1,431.4 million and $382.2 million, a significant share of total assets of $2,836.1 million.

Follow one dollar

Of each $1.00 of revenue in FY2011, Idex kept $0.11.

  1. Revenue$1.84B100.0%
  2. Cost of revenue−$1.10B59.8%
  3. Gross profit$738.7M40.2%
  4. Operating costs−$434.0M23.6%
  5. Operating income$304.7M16.6%
  6. Interest, other & tax−$110.8M6.0%
  7. Net income$193.9M10.5%
Computed from 10-KFY2011filed February 24, 2012Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2011 revenue went

$1.84B
  • Cost of revenue: $1.10B, 60% of revenue
  • SG&A: $421.7M, 23% of revenue
  • Net income: $193.9M, 11% of revenue
  • R&D: $36.0M, 2.0% of revenue
  • Interest, other & tax: $110.8M, 6.0% of revenue

Kept 11% as net income

Full revenue history →

Financial Statements

FY2011 against FY2010

Line itemFY2011FY2010Change
Revenue$1.84B$1.51B+21.5%
Cost of Revenue$1.10B$894.59M+22.9%
Gross Profit$738.67M$618.48M+19.4%
R&D Expenses$36.00M$31.80M+13.2%
SG&A Expenses$421.70M$358.27M+17.7%
Operating Income$304.66M$249.12M+22.3%
Interest Expense$29.33M$16.15M+81.6%
Net Income$193.86M$157.10M+23.4%
EPS (Basic)$2.34$1.93+21.2%
EPS (Diluted)$2.32$1.90+22.1%
Shares Outstanding (Basic)82.14M80.47M+2.1%
Shares Outstanding (Diluted)83.54M81.98M+1.9%

Frequently Asked Questions

  1. How did IDEX perform financially in 2011?

    Net sales were $1,838.5 million, up 22% from 2010. Operating income was $304.7 million, net income was $193.9 million, and diluted EPS was $2.32, compared with $1.90 in 2010. Organic sales rose 9%, with acquisitions contributing 11% and favorable currency translation 2%.

  2. What drove the growth in Health & Science Technologies?

    Segment sales rose 47% to $622.3 million, with acquisitions contributing 37% and organic growth 9%. Acquisitions in the segment included PPE, Fitzpatrick, AT Films, Microfluidics and CVI Melles Griot. Segment operating margin fell to 17.8% from 20.6%, mainly due to an inventory fair value charge tied to the CVI Melles Griot acquisition.

  3. How is the company financing its growth and what is its debt position?

    Total borrowings rose to $808.8 million at year-end 2011 from $527.9 million. The company issued $350.0 million of 4.2% senior notes due 2021 in December 2011 and used proceeds to repay bank debt, and it had $50.8 million outstanding under its $700.0 million revolving facility. The interest coverage ratio was 12.4 to 1 and the leverage ratio was 2.2 to 1, within covenant requirements of at least 3.0 to 1 and at most 3.25 to 1.

  4. What is the company's outlook for 2012?

    Management expects mid-single digit organic growth in 2012 and forecasts fully diluted EPS of $2.74 to $2.82. Effective in 2012, the company will realign its reportable segments to fold Dispensing Equipment into Fire & Safety/Diversified Products.

  5. What are the main risks flagged in the filing?

    The filing highlights exposure to economic conditions, with 53% of 2011 sales outside the U.S., and to foreign currency movements, particularly the Euro, Canadian Dollar, British Pound and Chinese Renminbi. It also notes risks from acquisitions and integration, and the large goodwill and intangible asset balances, whose write-off would adversely affect results. Asbestos-related lawsuits name the company and seven subsidiaries, but management does not currently believe they will have a material adverse effect.